TL;DR
Turn quiet afternoons into listening time
- Thousands of audiobooks, podcasts and originals
- Listen on your phone, tablet or Echo — also offline
- Cancel anytime
In a small single-arm study, 16 breast cancer survivors with cancer-related cognitive impairment who completed eight weeks of oxaloacetate had improved scores on a patient-reported cognitive measure. The findings are preliminary: there was no control group, and a randomized, placebo-controlled study is expected to begin enrolling before the end of 2026.
A small study found that 16 breast cancer survivors who completed eight weeks of oxaloacetate treatment reported improved cognitive function, with the group’s average score on a standardized measure rising from 29.1 to 55.5. The preliminary, uncontrolled findings suggest the supplement merits further testing for cancer-related cognitive impairment, but they do not establish that oxaloacetate caused the improvement.
The study enrolled 18 patients who were one to five years past cancer treatment and had cognitive impairment measured with the PROMIS questionnaire. Participants took 500 milligrams of oxaloacetate twice daily for eight weeks; 16 completed the study. The primary outcome was patients’ perceived cognitive impairment at the end of treatment.
Among those who completed the study, the mean score on the FACT-Cog PCI, a patient-reported measure of perceived cognitive function, rose from 29.1 at baseline to 55.5 after eight weeks. The report said the average moved from the impaired range to within the normal range. Improvements were observed at four weeks and generally increased over the remaining four weeks. Neuropsychological tests also showed gains in executive function and processing speed.
Researchers reported improvements in fatigue and physical functioning, as well as a trend toward improvement in insomnia. The most commonly reported side effects were gastrointestinal, including indigestion, bloating, constipation and diarrhea. The treatment was described as generally well tolerated, but the supplied report does not provide a full breakdown of adverse-event frequency or severity.
Why a Larger Trial Is Needed
Cancer-related cognitive impairment can affect thinking and daily life after treatment, and the source report describes it as a persistent concern for many cancer survivors. The study’s reported gains across patient-perceived cognition, fatigue and physical function make oxaloacetate a candidate for further research, particularly because pharmacologic options for this problem are limited.
But the results cannot show whether the supplement itself produced the changes. Without a comparison group, researchers cannot separate a treatment effect from factors such as expectations, natural changes over time or other influences. A randomized placebo-controlled trial can test whether the improvement is greater among people taking oxaloacetate than among people receiving a placebo.
As an affiliate, we earn on qualifying purchases.
How the Pilot Study Took Shape
Oxaloacetate is a naturally occurring human metabolite involved in intracellular energy production. It also has a role in regulating glutamate, a neurotransmitter involved in cognitive function. Earlier research, including studies of people with long COVID symptoms, provided a rationale for examining whether oxaloacetate might affect cognition or fatigue. Those findings do not establish its effectiveness for cancer-related impairment.
The researchers initially set a success threshold of a four-point improvement on the FACT-Cog PCI among the first nine participants. The report says preliminary analysis found a 27-point improvement in that group. The investigators then changed the study design to complete the work with a smaller total sample and speed development of a randomized trial. That change, alongside the absence of a control group, reinforces why the results should be treated as preliminary.
The report notes that cognitive problems after cancer treatment are often called “chemo brain” or “brain fog” and can occur in people with cancers other than breast cancer. The causes and mechanisms remain unclear. The study focused on breast cancer survivors, so its results cannot establish whether oxaloacetate would have similar effects in other patient groups.
“These early findings give us a strong reason to continue studying oxaloacetate as a potential approach for managing cognitive problems after breast cancer treatment.”
— Patricia Ganz, MD, of UCLA Health, in a press release
PROMIS cognitive function questionnaire patient-reported outcome
As an affiliate, we earn on qualifying purchases.
As an affiliate, we earn on qualifying purchases.
What the Pilot Cannot Establish
The study had no control group and included only 18 enrolled patients, of whom 16 completed treatment. The findings therefore cannot determine whether oxaloacetate caused the changes, how it compares with placebo or other approaches, or whether the results would hold in a larger and more varied group. The report also does not establish how long any improvement lasts after treatment ends.
Researchers have not established the precise causes of cancer-related cognitive impairment, and the study does not show how oxaloacetate might affect the condition. The available report gives examples of gastrointestinal side effects but not enough detail to assess their rates or compare risks with benefits. Results from this small breast cancer survivor sample also cannot be assumed to apply to people with other cancers.
cancer-related cognitive impairment brain training workbook
As an affiliate, we earn on qualifying purchases.
As an affiliate, we earn on qualifying purchases.
A Placebo-Controlled Trial Is Planned
A phase II randomized, placebo-controlled study of oxaloacetate for cancer-related cognitive impairment is expected to begin enrollment before the end of 2026, according to the report. That trial is intended to compare outcomes between participants receiving the supplement and those receiving placebo, addressing a central limitation of the pilot study.
Key information still to come includes the trial’s enrollment size, eligibility criteria, planned follow-up period and outcome measures. Until results from a controlled study are available, the pilot findings do not show that oxaloacetate is an established treatment for cognitive problems after cancer therapy.
cancer survivor fatigue and cognitive support planner
As an affiliate, we earn on qualifying purchases.
As an affiliate, we earn on qualifying purchases.
Key Questions
What did the oxaloacetate study find?
Among 16 participants who completed eight weeks, the mean FACT-Cog PCI score increased from 29.1 to 55.5. Researchers also reported improvements in fatigue and physical functioning. The study was small and had no control group.
Does the study prove oxaloacetate treats chemo brain?
No. The findings are preliminary and cannot establish that oxaloacetate caused the reported improvements. A randomized, placebo-controlled trial is needed to test whether the supplement works better than placebo.
What dose did participants take?
Participants took 500 milligrams twice a day for eight weeks. This describes the study regimen, not a recommendation for individual use.
What side effects were reported?
The report lists indigestion, bloating, constipation and diarrhea among the most commonly reported adverse effects, and describes treatment as generally well tolerated. It does not provide a detailed account of how often or how severely these effects occurred.
When will the next study begin?
A phase II randomized, placebo-controlled study is expected to begin enrollment before the end of 2026. Further details, including its size and follow-up period, were not provided in the source report.
Source: rss
Halloween Picks
halloween
As an affiliate, we earn on qualifying purchases.
